Anika Therapeutics Inc. (ANIK)
$15.14
$0.02
(0.13%)
As on 07-May-2026 16:00EDT
Market cap
$201 Mln
Revenue (TTM)
$116 Mln
P/E Ratio
--
P/B Ratio
1.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
26.31
-
EV/EBITDA
8.2
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.8
-
Face value
--
-
Shares outstanding
13,305,624
10 Years Aggregate
CFO
$239.66 Mln
EBITDA
$234.00 Mln
Net Profit
$61.98 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
| 57.5 | 2.6 | 47.0 | 7.5 | -16.4 | -18.0 | -10.1 |
|
BSE Sensex*
| -8.6 | 3.8 | -7.4 | -4.1 | 8.2 | 9.5 | 11.9 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
| -41.6 | -27.2 | -23.4 | -17.4 | -20.8 | -12.7 | 54.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Anika Therapeutics (ANIK)
|
15.1 | 201.2 | 116.3 | -11.1 | -10.5 | -7.9 | -- | 1.5 |
| 13.7 | 4,344.8 | 2,323.3 | 137.9 | 12.3 | -- | 61.9 | 105.4 | |
| 0.5 | 21.4 | 4.2 | -3.6 | -55.0 | -0 | -- | 0.9 | |
| 51.1 | 5,598.4 | 769.1 | 47.9 | 5.4 | 7.5 | 149 | 8.6 | |
| 9.1 | 469.5 | 676.8 | -15.4 | 9.0 | -- | -- | 0.8 | |
| 3.1 | 1,150.8 | 839.3 | -57.5 | -2.3 | -7.1 | -- | 1.4 | |
| 8.1 | 5,723.6 | 7,682.7 | 438.7 | 15.9 | 7.5 | 12.2 | 0.9 | |
| 0.1 | 107.0 | 0.0 | -17.4 | -- | -- | -- | 14.4 | |
| 26.7 | 1,420.7 | 61.4 | -166.2 | -267.6 | -- | -- | 49.0 | |
| 23.6 | 932.2 | 734.9 | 9.3 | 2.6 | 1.3 | 182.2 | 1.5 |
Shareholding Pattern
View DetailsAbout Anika Therapeutics (ANIK)
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and... Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts. Address: 32 Wiggins Avenue, Bedford, MA, United States, 01730 Read more
-
President, CEO & Director
Dr. Cheryl Renee Blanchard Ph.D.
-
President, CEO & Director
Dr. Cheryl Renee Blanchard Ph.D.
-
Headquarters
Bedford, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Anika Therapeutics (ANIK)
What is the current share price of Anika Therapeutics Inc (ANIK) Today?
The share price of Anika Therapeutics Inc (ANIK) is $15.14 (NASDAQ) as of 07-May-2026 16:00 EDT. Anika Therapeutics Inc (ANIK) has given a return of -16.35% in the last 3 years.
What is the current PB & PE ratio of Anika Therapeutics Inc (ANIK)?
Since, TTM earnings of Anika Therapeutics Inc (ANIK) is negative, P/E ratio is not available.
The P/B ratio of Anika Therapeutics Inc (ANIK) is 1.49 times as on 07-May-2026, a 74 discount to its peers’ median range of 5.84 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-12.96
|
0.98
|
|
2024
|
-4.30
|
1.57
|
|
2023
|
-4.01
|
1.56
|
|
2022
|
-29.16
|
1.52
|
|
2021
|
125.14
|
1.80
|
What is the 52 Week High and Low of Anika Therapeutics Inc (ANIK)?
The 52-week high and low of Anika Therapeutics Inc (ANIK) are Rs 16.24 and Rs 7.87 as of 08-May-2026.
What is the market cap of Anika Therapeutics Inc (ANIK)?
Anika Therapeutics Inc (ANIK) has a market capitalisation of $ 201 Mln as on 07-May-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Anika Therapeutics Inc (ANIK)?
Before investing in Anika Therapeutics Inc (ANIK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.